Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

NCT02282982 · clinicaltrials.gov ↗
COMPLETED
Status
359
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie